Education
About Us
Working with TipRanks
Follow Us
Iradimed Corp (DE:46K)
FRANKFURT:46K
Earnings Data
Report Date
Jul 31, 2025TBA Not Confirmed
Period Ending
2025 (Q2)Consensus EPS Forecast
0.39Last Year’s EPS
0.37Same Quarter Last Year
Moderate Buy
Based on 2 Analysts Ratings
Earnings Call Summary
Earnings Call Date:May 05, 2025
|% Change Since: 9.66%
|Next Earnings Date:Jul 31, 2025
Earnings Call Sentiment|Neutral
The earnings call reflected a strong performance in key areas such as revenue growth and domestic sales, alongside successful engagement with regulatory agencies. However, challenges such as declining international sales and tariff uncertainties present potential hurdles. The sentiment is balanced with significant achievements and ongoing challenges.Company Guidance
During the IRADIMED Corporation's first-quarter 2025 earnings call, CEO Roger Susi provided guidance for the upcoming quarter and the full year. For Q2 2025, the company expects revenue between $19.7 million and $19.9 million, GAAP diluted earnings per share (EPS) between $0.37 and $0.40, and non-GAAP diluted EPS between $0.41 and $0.44. The full-year 2025 guidance includes projected revenue between $78 million and $82 million, GAAP diluted EPS of $1.55 to $1.65, and non-GAAP diluted EPS of $1.71 to $1.81. The guidance reflects confidence in sustained demand for their products, including the anticipated launch of the new 3870 MR IV pump, expected to contribute to revenue starting in late 2025 and significantly more in 2026. Additionally, IRADIMED remains optimistic despite potential risks associated with tariffs and regulatory challenges, as they continue to monitor and address these issues proactively.Record-Breaking Revenue
For the first quarter of 2025, IRADIMED Corporation achieved record revenue of $19.5 million, marking an 11% increase over the same period last year.
Strong Earnings Growth
GAAP diluted earnings per share increased 16% from Q1 of 2024, demonstrating strong profitability for the company.
IV Infusion Pump System Growth
The IV Infusion Pump Systems saw a 16% growth to $6 million, reflecting sustained demand.
Disposables Revenue Surge
Revenue from disposables increased by 23% to $4.9 million, indicative of higher pump utilization.
Domestic Sales Success
Domestic sales accounted for 82% of total revenue in Q1 2025, up from 76% in Q1 of 2024, with domestic revenue increasing by 19% to $16 million.
New Facility Progress
The new facility is nearing completion with an expected full operational start by end of July 2025.
Engagement with FDA
Quick response from the FDA on the 510(k) submission for the 3870 MR IV pump, indicating efficient progress.
DE:46K Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
DE:46K Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
May 05, 2025 | €46.05 | €47.65 | +3.46% |
Feb 13, 2025 | €57.64 | €57.15 | -0.86% |
Oct 31, 2024 | €47.57 | €47.97 | +0.83% |
Aug 01, 2024 | €41.88 | €42.28 | +0.94% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does Iradimed Corp (DE:46K) report earnings?
Iradimed Corp (DE:46K) is schdueled to report earning on Jul 31, 2025, TBA Not Confirmed.
What is Iradimed Corp (DE:46K) earnings time?
Iradimed Corp (DE:46K) earnings time is at Jul 31, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is the P/E ratio of Iradimed Corp stock?
The P/E ratio of Iradimed is N/A.
What is DE:46K EPS forecast?
DE:46K EPS forecast for the fiscal quarter 2025 (Q2) is 0.39.